Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients
Karyopharm Therapeutics is seeking accelerated approval for its…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Ninlaro Could Replace First-line Velcade in Older Myeloma Patients, Study Suggests
Older multiple myeloma patients who are unable to receive…
Dendritic Cell Vaccine in Immunotherapy Triple Combo Seen to Boost Immune Response to Myeloma in Early Study
A triple combination treatment — dendritic cell vaccination plus …
Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial
Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from…
Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US
Multiple myeloma patients whose cancer progresses early after first-line…
Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows
Twice‐weekly Ninlaro (ixazomib) plus Revlimid…
